Aclaris Therapeutics, Inc. (ACRS)

Price$3.98

Favorite Metrics

Price vs S&P 500 (26W)102.86%

Price vs S&P 500 (4W)1.55%

Market Capitalization$479.97M

All Metrics

Book Value / Share (Quarterly)$0.86

P/TBV (Annual)0.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-35.93%

Cash Flow / Share (Quarterly)$-0.40

Price vs S&P 500 (YTD)27.92%

Gross Margin (TTM)6.93%

Net Profit Margin (TTM)-829.58%

EPS (TTM)$-0.53

10-Day Avg Trading Volume1.31M

EPS Excl Extra (TTM)$-0.53

Revenue Growth (5Y)3.85%

EPS (Annual)$-0.53

ROI (Annual)-62.98%

Gross Margin (Annual)6.93%

Net Profit Margin (5Y Avg)-690.91%

Cash / Share (Quarterly)$0.75

Revenue Growth QoQ (YoY)-85.94%

ROA (Last FY)-40.46%

Revenue Growth TTM (YoY)-58.20%

EBITD / Share (TTM)$-0.59

ROE (5Y Avg)-58.84%

Operating Margin (TTM)-975.91%

Cash Flow / Share (Annual)$-0.40

P/B Ratio4.66x

P/B Ratio (Quarterly)3.16x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)58.78x

ROA (TTM)-35.91%

EPS Incl Extra (Annual)$-0.53

Current Ratio (Annual)3.36x

Quick Ratio (Quarterly)3.36x

3-Month Avg Trading Volume2.03M

52-Week Price Return233.05%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)61.33x

Asset Turnover (Annual)0.05x

52-Week High$4.89

Operating Margin (5Y Avg)-734.98%

EPS Excl Extra (Annual)$-0.53

CapEx CAGR (5Y)15.97%

Tangible BV CAGR (5Y)-5.47%

26-Week Price Return106.84%

Quick Ratio (Annual)3.36x

13-Week Price Return47.74%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.36x

Enterprise Value$460.009

Revenue / Share Growth (5Y)-15.95%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)0.46%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-829.58%

Cash / Share (Annual)$0.75

3-Month Return Std Dev155.50%

Gross Margin (5Y Avg)31.54%

Net Income / Employee (TTM)$-1

ROE (Last FY)-62.98%

EPS Basic Excl Extra (Annual)$-0.53

Receivables Turnover (TTM)2.66x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.53

Receivables Turnover (Annual)2.66x

ROI (TTM)-52.04%

P/S Ratio (TTM)61.33x

Pretax Margin (5Y Avg)-691.15%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)203.22%

Year-to-Date Return30.56%

5-Day Price Return-3.68%

EPS Normalized (Annual)$-0.53

ROA (5Y Avg)-43.11%

Net Profit Margin (Annual)-829.58%

Month-to-Date Return4.80%

Cash Flow / Share (TTM)$-1.65

EBITD / Share (Annual)$-0.59

Operating Margin (Annual)-975.91%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-58.84%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)0.47x

P/B Ratio (Annual)3.16x

Inventory Turnover (TTM)8.60x

Pretax Margin (TTM)-829.58%

Book Value / Share (Annual)$0.86

Price vs S&P 500 (13W)47.06%

Beta0.72x

Revenue / Share (TTM)$0.06

ROE (TTM)-52.04%

52-Week Low$1.08

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.23

4.21

4.27

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ACRSAclaris Therapeutics, Inc.	61.33x	-58.20%	6.93%	—	$3.98
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing immuno-inflammatory disease therapies, including candidates Zunsemetinib (an Oral MK2 Inhibitor), Lepzacitinib, ATI-2138 (an ITJ Inhibitor), and ATI-052. The company also operates a contract research segment providing laboratory services, though therapeutics drives the majority of revenue.